Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mander

Showing results (631-640 of 722) with videos related to

Pageof 73
Sort By:
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Global Change Biology|November 6, 2019
Refining the role of phenology in regulating gross ecosystem productivity across European peatlandsFranziska Koebsch, Oliver Sonnentag, Järvi Järveoja, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysC M Britten, C Gouttefangeas, M J P Welters, et al.
American Heart Journal|August 10, 2018
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trialOmar Mukhtar, Joseph Cheriyan, John R Cockcroft, et al.
Journal of Crohn'S & Colitis|October 11, 2021
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel DiseaseAhmed M I Elfiky, Mohammed Ghiboub, Andrew Y F Li Yim, et al.
Nature|July 31, 2012
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage responseLaurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
The International Journal of Eating Disorders|February 3, 2017
A meta-analysis of the relation between therapeutic alliance and treatment outcome in eating disordersTiffany A Graves, Nassim Tabri, Heather Thompson-Brenner, et al.
Biotechnology for Biofuels|August 4, 2015
Closely related fungi employ diverse enzymatic strategies to degrade plant biomassIsabelle Benoit, Helena Culleton, Miaomiao Zhou, et al.
Nature Chemical Biology|March 26, 2013
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding groupMercedes Lobera, Kevin P Madauss, Denise T Pohlhaus, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Pageof 73

Showing results (631-640 of 722) with videos related to

Sort By:
Pageof 73
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Global Change Biology|November 6, 2019
Refining the role of phenology in regulating gross ecosystem productivity across European peatlandsFranziska Koebsch, Oliver Sonnentag, Järvi Järveoja, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysC M Britten, C Gouttefangeas, M J P Welters, et al.
American Heart Journal|August 10, 2018
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trialOmar Mukhtar, Joseph Cheriyan, John R Cockcroft, et al.
Journal of Crohn'S & Colitis|October 11, 2021
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel DiseaseAhmed M I Elfiky, Mohammed Ghiboub, Andrew Y F Li Yim, et al.
Nature|July 31, 2012
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage responseLaurens Kruidenier, Chun-wa Chung, Zhongjun Cheng, et al.
The International Journal of Eating Disorders|February 3, 2017
A meta-analysis of the relation between therapeutic alliance and treatment outcome in eating disordersTiffany A Graves, Nassim Tabri, Heather Thompson-Brenner, et al.
Biotechnology for Biofuels|August 4, 2015
Closely related fungi employ diverse enzymatic strategies to degrade plant biomassIsabelle Benoit, Helena Culleton, Miaomiao Zhou, et al.
Nature Chemical Biology|March 26, 2013
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding groupMercedes Lobera, Kevin P Madauss, Denise T Pohlhaus, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Pageof 73